
Eli Lilly and Company
NYSE•LLY
CEO: Mr. David A. Ricks
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 1972-06-01
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Contact Information
Market Cap
$971.05B
P/E (TTM)
52.7
47.9
Dividend Yield
0.6%
52W High
$1.13K
52W Low
$623.78
52W Range
Rank17Top 4.2%
6.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$17.60B+53.86%
4-Quarter Trend
EPS
$6.22+475.93%
4-Quarter Trend
FCF
$8.61B-1976.66%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Net Income Soars Net income reached $14.00 B for nine months ended September 30, 2025, marking a substantial 127% increase over prior year.
Quarterly Revenue Growth Strong Q3 2025 Revenue hit $17.60 B, showing 54% growth driven by volume increases in key products like Mounjaro.
Key Product Sales Explode Mounjaro Q3 revenue grew 109% to $6.52 B; Zepbound Q3 revenue surged 185% to $3.59 B compared to 2024.
Operating Cash Flow Doubles Net cash provided by operating activities was $13.59 B for nine months, more than double the $6.34 B provided in 2024.
Risk Factors
Pricing Pressure Uncertainty Ongoing governmental focus on drug pricing, including MFN initiatives, creates uncertainty impacting future realized prices and reimbursement.
R&D Investment Costs Rise Research and development expenses increased 20% for nine months to $9.54 B, driven by early and late-stage portfolio investments.
Incretin Supply Constraints Demand for incretin medicines exceeds production capacity; complex supply chain may cause periodic unavailability of certain dose levels.
Litigation Exposure Remains Company faces multiple ongoing legal proceedings, including insulin pricing and patent challenges, with uncertain resolution timelines.
Outlook
Pipeline Regulatory Submissions Submitted applications for tirzepatide pediatric use and insulin efsitora alfa; Donanemab received EC approval for Alzheimer's.
Share Repurchase Program $12.40 B remains authorized for share repurchases under the December 2024 program; $2.60 B repurchased in 9M 2025.
Manufacturing Capacity Expansion Capital expenditures are increasing significantly over several years to expand global manufacturing capacity for existing and future products.
Future IPR&D Investment Acquired $2.38 B in IPR&D during nine months, primarily related to acquisitions of Scorpion and SiteOne programs.
Peer Comparison
Revenue (TTM)
JNJ$92.15B
MRK$64.24B
PFE$62.79B
Gross Margin (Latest Quarter)
LLY82.9%
MRK81.9%
AZN81.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| LLY | $971.05B | 52.7 | 102.3% | 37.0% |
| JNJ | $505.28B | 20.3 | 32.7% | 3.3% |
| ABBV | $388.93B | 162.9 | 498.8% | 51.3% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
9.2%
Steady Growth
4Q Net Income CAGR
8.2%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 5, 2026
EPS:$7.47
|Revenue:$17.86B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $17.60B+53.9%|EPS: $6.22+475.9%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $15.56B+37.6%|EPS: $6.30+91.5%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 1, 2025|Revenue: $12.73B+45.2%|EPS: $3.07+23.3%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 19, 2025|Revenue: $45.04B+32.0%|EPS: $11.76+101.7%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 30, 2024|Revenue: $11.44B+20.4%|EPS: $1.08-1885.1%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 8, 2024|Revenue: $11.30B+36.0%|EPS: $3.29+76.9%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 30, 2024|Revenue: $8.77B+26.0%|EPS: $2.49+75.4%MeetForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 21, 2024|Revenue: $34.12B+19.6%|EPS: $5.83-11.3%Beat